Industry Trends

Webinar Date/Time: Thu, Mar 28, 2024 2:00 PM EDT

The FDA granted accelerated approval to Elahere in November 2022 for adults with folate receptor-alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Entrenched and emerging hurdles alike are challenging manufacturer pricing and access strategies.

Key steps in relationship-building beyond just treatment options.

As the market for biosimilars expands, a nuanced approach is needed to balance cost considerations with patient safety and pharmacovigilance efforts.

Cancer & Work: Acting Together guarantees job security and full salary continuation for up to twelve months for Sanofi employees and family members diagnosed with critical illnesses.

Synchron’s brain-computer interface device is being developed to allow patients with mobility challenges to operate certain technology with their mind.

By capitalizing on AI advancements, pushing the boundaries of personalized medicine with theranostics, and strengthening digital healthcare networks, radiopharmaceuticals are poised to transform healthcare from a reactive to a proactive discipline.

The US Department of Health and Human Services has initiated a comprehensive strategy to address the escalating syphilis rates, as a result.

Dr. Chris Smyth, president of ICON Biotech, discusses emerging trends in the biotech space.

JAMA study evaluates a potential correlation between new recreational cannabis laws and a possible reduction in synthetic opioid deaths.

In an interview with Pharm Exec Associate Editor Don Tracy, Ron Lanton, Partner, Lanton Law PLLC, discusses recent moves by CVS and Express Scripts to follow Mark Cuban's Cost Plus Drugs model.

Substance use disorder is a complex condition that demands innovative solutions, one of which that has shown promise is the use of long-acting injectables.

Report comes after the FDA seized thousands of counterfeit Ozempic units.

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.

Webinar Date/Time: Wednesday, March 6th, 2024 at 11am EST | 8am PST | 4pm GMT | 5pm CET

Under the agreement, Bristol Myers Squibb obtains Mirati’s entire portfolio, including Krazati (adagrasib) for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer.

Sun Pharmaceutical Industries will purchase Taro's outstanding shares for $43 each, which will total $348 million.

Webinar Date/Time: Thu, Feb 15, 2024 11:00 AM EST

In an interview with Nicholas Saraceno, Bill Roth, General Manager, Managing Partner, Blue Fin Group, discusses changes that will come with the pharma giant's new platform.

Experts weigh in on recent trends regarding weight loss medication and how they expect those trends to evolve in the coming year.

Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.

Generative artificial intelligence, key new product launches, and the evolution of the go-to-market model are among key trends to watch in the year ahead.

Investors may be attracted to precision medicine and gene therapy in the coming year due to a variety of reasons, including the treatments’ abilities to produce exact responses.

Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.